{"transactions":[{"id":710468,"issuer":{"id":8466,"kind":"organization","name":"Change Agents Corporation."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (right to buy)","published_at":"2026-07-13T20:30:29.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the Option shall vest in full on the grant date."}],"balance_after":101586,"derivative":{"exercise_price":0.282,"exercise_date":"2026-06-29","expiration_date":"2029-06-29","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-077588","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569735/000121390026077588/ownership.xml","form_type":"4"}},{"id":717498,"issuer":{"id":6975,"kind":"organization","name":"NOMAD POWER SOLUTIONS, INC."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:08:02.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of 30,000 restricted share units (\"RSUs\"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 30,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total reported in Column 5 includes (i) the 30,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001493152-26-031882","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226031882/ownership.xml","form_type":"4"}},{"id":805271,"issuer":{"id":6975,"kind":"organization","name":"NOMAD POWER SOLUTIONS, INC."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-17T20:15:37.000Z","date":"2026-04-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the \"Options\") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units (\"RSUs\"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled Options provided for vesting 50% on the grant date, the remaining 50% vesting in equal installments of 12.5% on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.05,"expiration_date":"2030-12-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-26-017852","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226017852/ownership.xml","form_type":"4"}},{"id":805270,"issuer":{"id":6975,"kind":"organization","name":"NOMAD POWER SOLUTIONS, INC."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-17T20:15:37.000Z","date":"2026-04-15","kind":"grant","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the \"Options\") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units (\"RSUs\"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001493152-26-017852","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226017852/ownership.xml","form_type":"4"}},{"id":958025,"issuer":{"id":6975,"kind":"organization","name":"NOMAD POWER SOLUTIONS, INC."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-30T00:19:12.000Z","date":"2025-12-24","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fifty percent (50%) of the option vested and became exercisable on the grant date. The remaining fifty percent (50%) vests in equal installments of twelve and one-half percent (12.5%) on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested, subject to the reporting person's continuous service through each applicable vesting date."}],"balance_after":25000,"derivative":{"exercise_price":4.05,"exercise_date":"2025-12-24","expiration_date":"2030-12-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-25-029459","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225029459/ownership.xml","form_type":"4"}},{"id":1064151,"issuer":{"id":8569,"kind":"organization","name":"La Rosa Holdings Corp."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-19T01:01:59.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of restricted common stock, vesting on the date of the grant, granted pursuant to the Second Amended and Restated La Rosa Holdings Corp. 2022 Equity Incentive Plan."}],"balance_after":600,"source":{"system":"sec-edgar","filing":"0001213900-25-078102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879403/000121390025078102/ownership.xml","form_type":"4"}},{"id":1289372,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2025-01-31T13:50:18.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":13158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"These shares were issued to Ms. Felix pursuant to the Director Agreement. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38."}],"balance_after":843578,"source":{"system":"sec-edgar","filing":"0001477932-25-000576","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793225000576/form4.xml","form_type":"4"}},{"id":1289371,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2025-01-31T13:50:18.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":15625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement (the \"Director Agreement\"), dated March 1, 2019, by and between the Company and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32."}],"balance_after":830420,"source":{"system":"sec-edgar","filing":"0001477932-25-000576","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793225000576/form4.xml","form_type":"4"}},{"id":1289370,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2025-01-31T13:50:18.000Z","date":"2024-07-02","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were issued to Ms. Felix pursuant to a Stock Grant Award Agreement (the \"Award Agreement\") by and between the Company and Ms. Felix, dated July 2, 2024. Pursuant to the Award Agreement, in recognition of Ms. Felix's services to the Company, and for assuming additional responsibilities, the Company issued 500,000 shares of Common Stock to Ms. Felix, representing an amount equal to $235,000, or $0.32 per share based on the closing price of the Common Stock on the date of issuance. These shares are subject to lock-up obligations for a period of 180 days following the date on which the Company's securities become listed for trading on a national securities exchange."},{"field":"kind","element":"transactionCoding","label":"F3","text":"These shares are subject to lock-up obligations for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act of 1933, as amended, pursuant to which the Company's securities become listed for trading on a national securities exchange or such longer period to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation."}],"balance_after":814795,"source":{"system":"sec-edgar","filing":"0001477932-25-000576","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793225000576/form4.xml","form_type":"4"}},{"id":1289369,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2025-01-31T13:50:18.000Z","date":"2024-04-24","kind":"grant","planned":false,"acquired":true,"shares":224196,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to an Exchange Agreement (the \"April 2024 Exchange Agreement\") by and between BioCorRx Inc. (the \"Company\") and Ms. Felix dated April 24, 2024. Pursuant to the April 2024 Exchange Agreement, Ms. Felix agreed to the exchange of directors fees in the amount of $265,000 for 224,196 shares of the Company's common stock, par value $0.001 per share (the \"Common Stock\") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance."}],"balance_after":314795,"source":{"system":"sec-edgar","filing":"0001477932-25-000576","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793225000576/form4.xml","form_type":"4"}},{"id":1458264,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2024-07-08T19:47:16.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":10204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.49."}],"balance_after":90599,"source":{"system":"sec-edgar","filing":"0001477932-24-004103","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793224004103/form4.xml","form_type":"4"}},{"id":1549344,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2024-04-03T10:05:43.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":5566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90."}],"balance_after":80395,"source":{"system":"sec-edgar","filing":"0001477932-24-001806","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793224001806/form4.xml","form_type":"4"}},{"id":1687628,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2024-01-04T22:00:04.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":6173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.81."}],"balance_after":74829,"source":{"system":"sec-edgar","filing":"0001477932-24-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793224000043/form4.xml","form_type":"4"}},{"id":1770321,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2023-10-02T20:30:13.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75."}],"balance_after":68656,"source":{"system":"sec-edgar","filing":"0001477932-23-007294","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793223007294/primary_doc.xml","form_type":"4"}},{"id":1835980,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2023-07-05T21:03:08.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":2891,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73."}],"balance_after":65798,"source":{"system":"sec-edgar","filing":"0001477932-23-005016","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793223005016/form4.xml","form_type":"4"}},{"id":1932247,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2023-04-03T22:28:50.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":2824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77."}],"balance_after":62907,"source":{"system":"sec-edgar","filing":"0001477932-23-002224","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793223002224/form4.xml","form_type":"4"}},{"id":2067069,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2023-01-04T21:15:28.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":5319,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94."}],"balance_after":60083,"source":{"system":"sec-edgar","filing":"0001477932-23-000087","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793223000087/form4.xml","form_type":"4"}},{"id":2142136,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2022-10-05T19:48:16.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":2450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04."}],"balance_after":54764,"source":{"system":"sec-edgar","filing":"0001477932-22-007465","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793222007465/form4.xml","form_type":"4"}},{"id":2210706,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2022-07-07T22:06:03.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":2092,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.39."}],"balance_after":52314,"source":{"system":"sec-edgar","filing":"0001477932-22-004883","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793222004883/form4.xml","form_type":"4"}},{"id":2308009,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2022-04-04T21:29:41.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":1408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.55."}],"balance_after":50222,"source":{"system":"sec-edgar","filing":"0001477932-22-002037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793222002037/form4.xml","form_type":"4"}},{"id":2360397,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2022-03-02T20:14:34.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":1141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.38."}],"balance_after":48814,"source":{"system":"sec-edgar","filing":"0001477932-22-001168","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793222001168/form4.xml","form_type":"4"}},{"id":2535487,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2021-10-25T20:07:54.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":1381,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.62."}],"balance_after":47673,"source":{"system":"sec-edgar","filing":"0001477932-21-007562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793221007562/form4.xml","form_type":"4"}},{"id":2641065,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2021-07-07T00:23:49.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":1210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.13."}],"balance_after":46292,"source":{"system":"sec-edgar","filing":"0001477932-21-004470","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793221004470/form4.xml","form_type":"4"}},{"id":2761091,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2021-04-02T15:52:45.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":2326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.15."}],"balance_after":45082,"source":{"system":"sec-edgar","filing":"0001477932-21-002006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793221002006/form4.xml","form_type":"4"}},{"id":3008121,"issuer":{"id":8179,"kind":"organization","name":"BioCorRx Inc."},"owners":[{"id":30754,"kind":"person","name":"Felix Lourdes","position":1,"cik":"0001569735","reported_name":"Felix Lourdes","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock, par value $0.001","published_at":"2020-10-13T22:35:04.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":2631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.90."}],"balance_after":37855,"source":{"system":"sec-edgar","filing":"0001477932-20-005860","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1443863/000147793220005860/form4.xml","form_type":"4"}}]}